1
|
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 2024:S0923-7534(24)00046-2. [PMID: 38369015 DOI: 10.1016/j.annonc.2024.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 02/05/2024] [Accepted: 02/08/2024] [Indexed: 02/20/2024] Open
Abstract
BACKGROUND KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy. In this preplanned exploratory analysis, we assessed RCB distribution and EFS within RCB categories by treatment group. PATIENTS AND METHODS A total of 1174 patients with stage T1c/N1-2 or T2-4/N0-2 TNBC were randomized 2 : 1 to pembrolizumab 200 mg or placebo every 3 weeks given with four cycles of paclitaxel + carboplatin, followed by four cycles of doxorubicin or epirubicin + cyclophosphamide. After surgery, patients received pembrolizumab or placebo for nine cycles or until recurrence or unacceptable toxicity. Primary endpoints are pCR and EFS. RCB is a prespecified exploratory endpoint. The association between EFS and RCB was assessed using a Cox regression model. RESULTS Pembrolizumab shifted patients into lower RCB categories across the entire spectrum compared with placebo. There were more patients in the pembrolizumab group with RCB-0 (pCR), and fewer patients in the pembrolizumab group with RCB-1, RCB-2, and RCB-3. The corresponding hazard ratios (95% confidence intervals) for EFS were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23). The most common first EFS events were distant recurrences, with fewer in the pembrolizumab group across all RCB categories. Among patients with RCB-0/1, more than half [21/38 (55.3%)] of all events were central nervous system recurrences, with 13/22 (59.1%) in the pembrolizumab group and 8/16 (50.0%) in the placebo group. CONCLUSIONS Addition of pembrolizumab to chemotherapy resulted in fewer EFS events in the RCB-0, RCB-1, and RCB-2 categories, with the greatest benefit in RCB-2. These findings demonstrate that pembrolizumab not only increased pCR rates, but also improved EFS among most patients who do not have a pCR.
Collapse
Affiliation(s)
- L Pusztai
- Yale School of Medicine, Yale Cancer Center, New Haven, USA.
| | - C Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology Network, Dallas, USA
| | - J Cortes
- International Breast Cancer Center, Quironsalud Group, Barcelona; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
| | - R Dent
- National Cancer Center Singapore, Duke - National University of Singapore Medical School, Singapore, Singapore
| | - H McArthur
- University of Texas Southwestern Medical Center, Dallas, USA
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen; Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Solna, Sweden
| | - Y H Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - R Hui
- Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, Australia
| | - N Harbeck
- Breast Center, Department of Obstetrics and Gynaecology, LMU University Hospital, Munich, Germany
| | - M Takahashi
- Hokkaido University Hospital, Sapporo, Japan
| | - M Untch
- Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin
| | - P A Fasching
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
| | - Y Zhu
- Oncology, Merck & Co., Inc., Rahway, USA
| | - W Pan
- Oncology, Merck & Co., Inc., Rahway, USA
| | | | - P Schmid
- Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK
| |
Collapse
|
2
|
Kümmel S, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, Cortes J, McArthur H, Dent R, O’Shaughnessy J, Pusztai L, Foukakis T, Park Y, Hui R, Cardoso F, Denkert C, Zhu Y, Pan W, Karantza V, Fasching P. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. Breast 2023. [DOI: 10.1016/s0960-9776(23)00242-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
3
|
Paepke S, Klein E, Andrulat A, Ankel C, Bauer L, Faridi A, Fink V, Gerber-Schäfer C, Gschwantler-Kaulich D, Heil J, Kümmel S, Ohlinger R, Thill M. Mesh-Pocket Supported Prepectoral Direct-to-Implant Breast Reconstruction: Preliminary Results of a Prospective Analysis. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01378-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Tonk C, Schinköthe T, Harbeck N, Carmelo V, Gomes Feliciano J, Wuerstlein R, Kümmel S, Schmidt A. AI-based smartphone App using a single-lead ECG for automated QTc diagnostics in oncology. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01540-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Paepke S, Andrulat A, Ankel C, Bauer L, Baumann K, Blohmer J, Faridi A, Fink V, Gerber-Schäfer C, Gschwantler-Kaulich D, Heil J, Kümmel S, Mau C, Kossmann-Meiré A, Ohlinger R, Thill M. Underestimated risk of involved margins in Skin (SMM)- and Nipple Sparing Mastectomies (NSM) – Data and Multimodal Approach for Improvement. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01379-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Trepl T, Schelter I, Kümmel S. Analyzing Excitation-Energy Transfer Based on the Time-Dependent Density Functional Theory in Real Time. J Chem Theory Comput 2022; 18:6577-6587. [PMID: 36268773 DOI: 10.1021/acs.jctc.2c00600] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Excitation-energy transfer is a key step in processes such as photosynthesis that convert light into other forms of energy. Time-dependent density functional theory (DFT) in real time is ideal for the first-principles simulation of such processes due to its computational efficiency. We here demonstrate how real-time DFT can be used for analyzing excitation-energy transfer from first-principles. We discuss several measures of energy transfer that are based solely on the time-dependent density, are well founded in the DFT framework, allow for intuitive understanding and visualization, and reproduce important limiting cases of an analytical model. We demonstrate their usefulness in calculations for model systems, both with static nuclei and in the context of DFT-based Ehrenfest dynamics.
Collapse
Affiliation(s)
- T Trepl
- Theoretical Physics IV, University of Bayreuth, Bayreuth95440, Germany
| | - I Schelter
- Theoretical Physics IV, University of Bayreuth, Bayreuth95440, Germany
| | - S Kümmel
- Theoretical Physics IV, University of Bayreuth, Bayreuth95440, Germany
| |
Collapse
|
7
|
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol 2022; 33:743-744. [PMID: 35595658 DOI: 10.1016/j.annonc.2022.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main.
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin
| | | | - J Huober
- Brustzentrum, Universitätsfrauenklinik Ulm, Ulm
| | - B V Sinn
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin; Berlin Institute of Health (BIH), Berlin
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin
| | | | | | - H Tesch
- Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main
| | - C Hanusch
- Rotkreuzklinikum München Frauenklinik, München
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss
| | - M Rezai
- Medical Center, Luisenkrankenhaus Düsseldorf, Düsseldorf
| | - C Jackisch
- Brustzentrum, Sana-Klinikum Offenbach, Offenbach
| | - W D Schmitt
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | | | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen
| | - B Rautenberg
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg
| | - P A Fasching
- Brustzentrum, Universitätsklinikum Erlangen, Erlangen
| | - K Weber
- German Breast Group, Neu-Isenburg
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne
| | - C Denkert
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
8
|
Schmid P, Gomez-Pardo P, Wheatley D, Roy P, Krabisch P, Thill M, Ledwidge S, Thompson A, Macaskill E, Viehstädt N, Purushotham A, Gluz O, Stefek A, Ackerman C, Prendergast A, Mousa K, Jones L, Viale G, Cortés J, Kümmel S. 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Ding Y, Tryfonidis K, Aktan G, Karantza V, O’Shaughnessy J. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.06.014] [Citation(s) in RCA: 70] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
10
|
Carey L, Pierga JY, Kümmel S, Jerusalem G, De Laurentiis M, Miller M, Li Z, Kaper M, Su F, Loi S. 275P A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Loibl S, Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Kümmel S, Mundhenke C, Hoffmann O, Zahn MO, Müller L, Denkert C, van Mackelenbergh M, Fasching P, Burchardi N, Nekljudova V. LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Swain S, Tan A, Gianni L, Kümmel S, Dang C, Schneeweiss A, O'Shaughnessy J, Liu H, Aguila C, Heeson S, Macharia H, Restuccia E, Loibl S. 138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Vlachou E, Kümmel S, Künzel N, Breit E, Schindowski D, Pankert K, Hentsch S, Hanf V, Weber D, Graßhoff ST, Müller C, Lucke W, Deuschle P, Engellandt K, Rüland A, Dall P, Harrach H, Bruzas S, Chiari O, Reinisch M. 201TiP Evaluation of the feasibility of ultrasound-guided clipping of suspicious intramammary lesions in primary breast cancer patients receiving neoadjuvant therapy (Ultra3Detect). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
14
|
Paepke S, Thill M, Peisker U, Ohlinger R, Gruber I, Malter W, Kümmel S, Hahn M, Kühn T, Reinisch M, Stachs A, Reimer T. One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results. Breast 2021. [DOI: 10.1016/s0960-9776(21)00172-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
15
|
Paepke S, Kiechle M, Gerber-Schäfer C, Kümmel S, Faridi A, Bauer L, Thill M, Ankel C, Andrulat A, Gschwantler-Kaulich D, Heil J, Fink V, Ohlinger R. Präpektorale Implantateinlage in der plastisch-rekonstruktiven Mammachirurgie unter Verwendung des TiLOOP Bra Pocket – erste Daten der PRO-Pocket Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Paepke
- Klinikum rechts der Isar,pechnische Universität München
| | - M Kiechle
- Klinikum rechts der Isar,pechnische Universität München
| | | | | | | | | | - M Thill
- Agaplesion Markus Krankenhaus
| | | | | | | | - J Heil
- Universitätsklinikum Heidelberg
| | | | | |
Collapse
|
16
|
Bruzas S, Kümmel S, Harbeck N, Schmid P, Cortés J, Seiberling C, Chiari O, Harrach H, Ataseven B, Dyson M, Traut E, Theuerkauf I, Gebauer D, Gluz O, Reinisch M. 172P Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Martínez SG, Mies BP, Casas TC, Rosa JR, Peralto JR, Curigliano G, Schmid P, Kümmel S, Garcia JP, Miranda EL, Cortes MG, Calvo JP, Cortés J. 298P Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Peuker CA, Yaghobramzi S, Lüftner D, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Busse A. Einfluss des CDK4/6-Inhibitors Ribociclib auf die periphere Immunantwort beim Hormonrezeptor-positiven Mammakarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1714608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
Affiliation(s)
- CA Peuker
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | - S Yaghobramzi
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | - D Lüftner
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| | | | - T Decker
- Gemeinschaftspraxis Onkologie Ravensburg
| | - P Fasching
- Frauenklinik, Universitätsklinikum Erlangen
| | - T Fehm
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf
| | - W Janni
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm
| | - S Kümmel
- Klinik für Senologie/Interdisziplinäres Brustkrebszentrum, Kliniken Essen-Mitte
| | - A Schneeweiss
- Klinik für Frauenheilkunde und Geburtshilfe, Universität Heidelberg
| | - M Schuler
- Klinik für Medizinische Onkologie, Universitätsklinikum Essen
| | - A Busse
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie, Onkologie und Tumorimmunologie
| |
Collapse
|
19
|
Schmid P, Kümmel S, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Singel S, Withana N, Mani A, Li S, Harris A, Wongchenko M, Sablin M. Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1714585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
Affiliation(s)
| | | | | | - P Savas
- Peter MacCallum Cancer Centre
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2020; 30:1279-1288. [PMID: 31095287 DOI: 10.1093/annonc/mdz158] [Citation(s) in RCA: 387] [Impact Index Per Article: 96.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. PATIENTS AND METHODS GeparNuevo is a randomised phase II double-blind placebo-controlled study randomising patients with TNBC to durvalumab or placebo given every 4 weeks in addition to nab-paclitaxel followed by standard EC. In the window-phase durvalumab/placebo alone was given 2 weeks before start of nab-paclitaxel. Randomisation was stratified by stromal tumour-infiltrating lymphocyte (sTILs). Patients with primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were included. Primary objective was pathological complete response (pCR) (ypT0 ypN0). RESULTS A total of 174 patients were randomised, 117 participated in the window-phase. Median age was 49.5 years (range 23-76); 47 patients (27%) were younger than 40 years; 113 (65%) had stage ≥IIA disease, 25 (14%) high sTILs, 138 of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4% (95% CI 42.5% to 61.4%) versus placebo 44.2% (95% CI 33.5% to 55.3%; unadjusted continuity corrected χ2P = 0.287), corresponding to OR = 1.45 (95% CI 0.80-2.63, unadjusted Wald P = 0.224). Durvalumab effect was seen only in the window cohort (pCR 61.0% versus 41.4%, OR = 2.22, 95% CI 1.06-4.64, P = 0.035; interaction P = 0.048). In both arms, significantly increased pCR (P < 0.01) were observed with higher sTILs. There was a trend for increased pCR rates in PD-L1-positive tumours, which was significant for PD-L1-tumour cell in durvalumab (P = 0.045) and for PD-L1-immune cell in placebo arm (P = 0.040). The most common immune-related adverse events were thyroid dysfunction any grade in 47%. CONCLUSIONS Our results suggest that the addition of durvalumab to anthracycline-/taxane-based NACT increases pCR rate particularly in patients treated with durvalumab alone before start of chemotherapy. TRIAL REGISTRATION ClinicalTrials.gov number: NCT02685059.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main.
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin
| | | | - J Huober
- Brustzentrum, Universitätsfrauenklinik Ulm, Ulm
| | - B V Sinn
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin; Berlin Institute of Health (BIH), Berlin
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin
| | | | | | - H Tesch
- Oncological Practice Bethanien, Cancer Center Frankfurt Northeast, Frankfurt am Main
| | - C Hanusch
- Rotkreuzklinikum München Frauenklinik, München
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss
| | - M Rezai
- Medical Center, Luisenkrankenhaus Düsseldorf, Düsseldorf
| | - C Jackisch
- Brustzentrum, Sana-Klinikum Offenbach, Offenbach
| | - W D Schmitt
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | | | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen
| | - B Rautenberg
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Freiburg
| | - P A Fasching
- Brustzentrum, Universitätsklinikum Erlangen, Erlangen
| | - K Weber
- German Breast Group, Neu-Isenburg
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne
| | - C Denkert
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| |
Collapse
|
21
|
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2019; 29:2341-2347. [PMID: 30335131 DOI: 10.1093/annonc/mdy460] [Citation(s) in RCA: 155] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and methods Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA). Results A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059). Conclusions The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany.
| | - K E Weber
- German Breast Group, Neu-Isenburg, Germany
| | - K M Timms
- Myriad Genetics Inc, Salt Lake City, USA
| | - E P Elkin
- The Permanente Medical Group Inc, Oakland, USA
| | - E Hahnen
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
| | - B Lederer
- German Breast Group, Neu-Isenburg, Germany
| | - C Denkert
- Institute of Pathology, Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - S Braun
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - C T Salat
- Hämatoonkologische Schwerpunktpraxis, Munich, Germany
| | - M Rezai
- Luisenkrankenhaus, Düsseldorf, Germany
| | - J U Blohmer
- Klinik für Gynäkologie mit Brustzentrum Charité, Berlin, Germany
| | - D M Zahm
- Brustzentrum SRH Waldklinikum, Gera, Germany
| | - C Jackisch
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - B Gerber
- Frauenklinik, Universität Rostock, Rostock, Germany
| | - P Klare
- Praxisklinik, Berlin, Germany
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | - C Schem
- Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany
| | - S Paepke
- Klinikum rechts der Isar der Technischen Universität München, Frauenklinik, München, Germany
| | - R Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - S Penn
- Myriad Genetics Inc, Salt Lake City, USA
| | - J Reid
- Myriad Genetics Inc, Salt Lake City, USA
| | | | | | | | - M Untch
- Helios-Klinikum Berlin-Buch, Berlin, Germany
| |
Collapse
|
22
|
Nabieva N, Kellner S, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann Oncol 2019; 29:186-192. [PMID: 29045642 DOI: 10.1093/annonc/mdx630] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. Patients and methods The EvAluate-TM study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase. Treatment persistence was evaluated at two pre-specified study visits after 6 and 12 months. As a measure of early therapy persistence the time from the start to the end of treatment (TTEOT) was analyzed. Cox regression analyses were carried out to identify patient characteristics and tumor characteristics predicting TTEOT. Results Out of the total population of 3941 patients with EBC, 540 (13.7%) events involving treatment cessation unrelated to disease progression were observed. This was due to drug-related toxicity in the majority of cases (73.5%). Persistence rates were 92.2%, 86.9%, and 86.3% after 6, 12, and 15 months, respectively. The main factors influencing premature treatment discontinuation were older age [hazard ratio (HR) 1.02/year], comorbidities (HR 1.06 per comorbidity), low body mass index, and lower tumor grade (HR 0.85 per grade unit). Conclusion These results support the view that older, multimorbid patients with low tumor grade and low body mass index are at the greatest risk for treatment discontinuation and might benefit from compliance and support programs.
Collapse
Affiliation(s)
- N Nabieva
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - S Kellner
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - T Fehm
- Department of Gynecology, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.,Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - L Häberle
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.,Biostatistics Unit, Department of Gynecology, Erlangen University Hospital, Erlangen, Germany
| | - J de Waal
- Department of Gynecology, Dachau Clinic, Dachau, Germany
| | - M Rezai
- Luisen-Hospital Düsseldorf, Düsseldorf, Germany
| | - B Baier
- Department of Gynecology, Dachau Clinic, Dachau, Germany
| | - G Baake
- Oncological Medical Practice Pinneberg, Pinneberg, Germany
| | | | | | - M Warm
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany.,Breast Center, Clinics of Cologne gGmbH, Holweide, Cologne, Germany
| | - N Harbeck
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany.,Breast Center, Department of Gynecology, University of Munich (LMU), Munich, Germany
| | - R Wuerstlein
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany.,Breast Center, Department of Gynecology, University of Munich (LMU), Munich, Germany
| | - J-U Deuker
- Vinzenz-Hospital Hannover GmbH, Hannover, Germany
| | - P Dall
- Department of Gynecology, Lüneburg Clinic, Lüneburg, Germany
| | - B Richter
- Elbland Clinics, Meissen-Radebeul, Germany
| | - G Wachsmann
- County Hospital of Böblingen, Böblingen, Germany
| | - C Brucker
- Department of Gynecology, University Hospital, Paracelsus Private Medical University of Nuremberg, Nuremberg, Germany
| | - J W Siebers
- Department of Gynecology, St. Josef's Hospital, Offenburg, Germany
| | - N Fersis
- Department of Gynecology, Bayreuth Clinic GmbH, CCC ER-EMN, Bayreuth, Germany
| | - T Kuhn
- Karl-Olga-Hospital Stuttgart, Diakonie Klinikum Stuttgart, Stuttgart, Germany
| | - C Wolf
- Medical Center Ulm, Ulm, Germany
| | - H-W Vollert
- Friedrichshafen Clinic, Friedrichshafen, Germany
| | - G-P Breitbach
- Department of Gynecology, Neunkirchen Clinic, Neunkirchen, Germany
| | - W Janni
- Department of Gynecology, Ulm University Hospital, Ulm, Germany
| | - R Landthaler
- Gynecological Medical Practice of the County Hospital of Krumbach, Krumbach, Germany
| | - A Kohls
- Protestant County Hospital of Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany
| | - D Rezek
- Marien-Hospital Wesel, Wesel, Germany
| | - T Noesselt
- Department of Gynecology of the County Hospital of Hameln, Hameln, Germany
| | - G Fischer
- Mittweida Hospital gGmbH, Mittweida, Germany
| | - S Henschen
- HELIOS Kliniken Schwerin GmbH, Schwerin, Germany
| | - T Praetz
- Caritas-Hospital Bad Mergentheim, Bad Mergentheim, Germany
| | - V Heyl
- Asklepios Paulinen Clinic Wiesbaden, Wiesbaden, Germany
| | - T Kühn
- Department of Gynecology, Esslingen Clinics a.N., Esslingen, Germany
| | - T Krauss
- Department of Gynecology Lippe-Detmold, Lippe-Detmold, Germany
| | - C Thomssen
- Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany
| | - A Hohn
- County Hospital of Rendsburg, Rendsburg, Germany
| | - H Tesch
- Oncology Bethanien Frankfurt, Frankfurt, Germany
| | - C Mundhenke
- Department of Gynecology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - A Hein
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C Rauh
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C M Bayer
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - A Jacob
- Novartis Pharma GmbH Nuremberg, Nuremberg, Germany
| | - K Schmidt
- Novartis Pharma GmbH Nuremberg, Nuremberg, Germany
| | | | - S Y Brucker
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - S Kümmel
- Breast Unit, Essen Mitte Clinics, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany
| | - M W Beckmann
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - D Wallwiener
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - P Hadji
- Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany
| | - P A Fasching
- Department of Gynecology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| |
Collapse
|
23
|
Fasching PA, Eggemann H, Krocker J, Häberle L, Volz B, Kleine-Tebbe A, Blohmer JU, Kittel K, Hufnagel M, Janni W, Emons G, Simon E, Köhler U, Thomssen C, Kohls A, Beckmann MW, Hielscher C, Krabisch P, Zeiser T, Brodkorb T, Baier F, Nabieva N, Kellner S, Untch M, Stadie S, Budner M, Breitbach GP, Keller M, Stickeler E, Kühn T, Tolkmitt M, Belau AK, Schmidt M, Ulm K, Kümmel S. Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-13-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Dose dense chemotherapy (DDT) has shown improvements of disease-free survival (DFS) and overall survival for primary breast cancer patients with a high risk of relapse. There are much less data about the effect of DDT in patients with intermediate risk of recurrence (1-3 positive axillary lymph nodes). Aim of this prospectively randomized trial was to investigate the superiority of a DDT schedule over a standard chemotherapy (ST) in primary breast cancer patients with 1-3 positive axillary lymph nodes.
Methods
The ASG1-3 study is a prospectively randomized, open label phase III study of the Adjuvant Study Group of the NOGGO association. Patients were eligible for the trial, if they had a primary invasive breast cancer (pT1-3) with 1-3 positive axillary lymph nodes and no evidence of distant metastases. Patients were randomized to an adjuvant therapy with either 4 cycles epirubicin (90mg/m2 body surface area, BSA) and cyclophosphamide (600mg/m2 BSA) q3w, followed by 4 cycles of paclitaxel (175mg/m2 BSA) referred to as ST or to a therapy with 4 cycles of epicubicin (120 mg/m2 BSA) q2w and primary G-CSF support followed by 4 cycles of paclitaxel (175mg/m2 BSA) q2w and primary G-CSF support referred to as DDT. Trastuzumab was not given in this study. The study was designed to show an increase of 70% DFS (ST) to 80% DFS (DDT) 5 years after randomization. Comparisons were conducted using Kaplan Meier estimates, log rank tests and Cox regression analyses. In an exploratory way, subgroup analyses were performed for HER2, hormone receptor status and grading using Cox regression models with interaction terms.
Results
A total of 936 patients were eligible for survival analysis, of which 465 were randomized to ST and 471 to DDT from 2001 to 2004. Patient characteristics were mainly well balanced, with patients being 52.5/52.1 years old, 71.9/78.1% being hormone receptor positive, 24.4/24.6% being HER2 positive and 38.6/38.8% having a tumor grade of 3 in the ST arm and DDT arm respectively. 53 events occurred after ST and 46 after DDT. Adjusted hazard ratio (HR) was 0.87 (95%CI: 0.57-1.35; p=0.54). 5 year DFS rates were 85% (ST) vs. 87% (DDT). Hematological toxicities were the most common grade 3 or 4 adverse events. Grade 3/4 neutropenia occurred in 57.2 vs. 28.0%, grade 3/4 anemia in 15.3% vs. 17.1% and grade 3 /4 pain symptoms were seen in 13.2 vs. 12.4% of the patients in the ST arm vs. DDT arm respectively. Other grade 3/4 toxicities were less frequent than 10%. Subgroup analysis showed a significant interaction (p<0.001) between HER2 status and randomization arm with regard to DFS. In HER2 negative patients the HR was 1.53 (95%CI: 0.91-2.59), whereas in HER2 positive patients the HR was 0.22 (95%CI: 0.09-0.55). Patients with HER2 positive disease and DDT had a similar prognosis like HER2 negative patients.
Conclusion
In the overall population a statistically significant improvement of DFS could not be shown for the DDT arm. In patients with HER2 positive breast cancer DDT chemotherapy improved the disease-free survival to a prognosis which was similar to patients with HER2 negative disease.
Citation Format: Fasching PA, Eggemann H, Krocker J, Häberle L, Volz B, Kleine-Tebbe A, Blohmer J-U, Kittel K, Hufnagel M, Janni W, Emons G, Simon E, Köhler U, Thomssen C, Kohls A, Beckmann MW, Hielscher C, Krabisch P, Zeiser T, Brodkorb T, Baier F, Nabieva N, Kellner S, Untch M, Stadie S, Budner M, Breitbach G-P, Keller M, Stickeler E, Kühn T, Tolkmitt M, Belau AK, Schmidt M, Ulm K, Kümmel S. Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-13-01.
Collapse
Affiliation(s)
- PA Fasching
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - H Eggemann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - J Krocker
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - L Häberle
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - B Volz
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - A Kleine-Tebbe
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - J-U Blohmer
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - K Kittel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Hufnagel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - W Janni
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - G Emons
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - E Simon
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - U Köhler
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - C Thomssen
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - A Kohls
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - MW Beckmann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - C Hielscher
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - P Krabisch
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Zeiser
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Brodkorb
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - F Baier
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - N Nabieva
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Kellner
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Untch
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Stadie
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Budner
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - G-P Breitbach
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Keller
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - E Stickeler
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Kühn
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Tolkmitt
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - AK Belau
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Schmidt
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - K Ulm
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Kümmel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| |
Collapse
|
24
|
Frindte J, Ataseven B, Harter P, Göke G, Podkowinkski J, Vogt C, Bluni V, Vincent M, Traut A, Heitz F, Kümmel S, Prader S, Bommert M, Schneider S, du Bois A. Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Frindte
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - B Ataseven
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - P Harter
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - G Göke
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - J Podkowinkski
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - C Vogt
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - V Bluni
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - M Vincent
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - A Traut
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - F Heitz
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - S Kümmel
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - S Prader
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - M Bommert
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - S Schneider
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - A du Bois
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| |
Collapse
|
25
|
Kümmel S, Tondini C, Abraham J, Nowecki Z, Itrych B, Hitre E, Karaszewska B, Juarez A, Morales-Vásquez F, Pérez García J, Cardona-Huerta S, Heinzmann D, He J, Duc A, Crepelle-Fléchais A, Martín M. Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Rhiem K, Warm M, Fasching P, Just M, Hanusch C, Hackmann J, Blohmer JU, Furlanetto J, Nekljudova V, von Minckwitz G, Loibl S. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, Kümmel S, Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- G Waldenfels
- Charité – Universitätsmedizin Berlin, Campus Mitte, Abteilung für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - S Loibl
- German Breast Group GmbH, Neu-Isenburg, Deutschland
| | - J Furlanetto
- German Breast Group GmbH, Neu-Isenburg, Deutschland
| | - A Machleidt
- Charité – Universitätsmedizin Berlin, Campus Mitte, Abteilung für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| | - B Lederer
- German Breast Group GmbH, Neu-Isenburg, Deutschland
| | - C Denkert
- Charité – Universitätsmedizin Berlin, Campus Mitte, Institut für Pathologie, Berlin, Deutschland
| | - C Hanusch
- Rotkreuzklinikum München, München, Deutschland
| | - S Kümmel
- Kliniken Essen Mitte, Essen, Deutschland
| | - G Minckwitz
- German Breast Group GmbH, Neu-Isenburg, Deutschland
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Deutschland
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin, Deutschland
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Universitätsklinik Köln, Köln, Deutschland
| | - PA Fasching
- Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - JU Blohmer
- Charité – Universitätsmedizin Berlin, Campus Mitte, Abteilung für Gynäkologie mit Brustzentrum, Berlin, Deutschland
| |
Collapse
|
28
|
Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Lindner C, Kümmel S, Kates R, Potenberg J, Staib P, Wuerstlein R, Kreipe H, Harbeck N. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Nabieva N, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Hack CC, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur J Cancer 2018; 96:82-90. [PMID: 29679775 DOI: 10.1016/j.ejca.2018.03.020] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Revised: 03/15/2018] [Accepted: 03/19/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor-positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuation. This analysis aimed to identify side-effects that lead to patients failing to persist with letrozole treatment. PATIENTS AND METHODS Post-menopausal hormone receptor-positive EBC patients starting ET with letrozole were enroled in EvAluate-TM, a non-interventional study. Information regarding treatment compliance and persistence was gathered in months 6 and 12. Persistence was defined as the time from 30 d after the start to the end of treatment. The influence on persistence of musculoskeletal syndrome, menopausal disorder, sleep disorder and other AEs within the first 30 d was analysed using Cox regression analyses. RESULTS Among 3887 patients analysed, the persistence rate after 12 months was >85%. In all, 568 patients (14.6%) discontinued the treatment, 358 of whom (63.0%) did so only because of side-effects. The main AEs influencing persistence were musculoskeletal symptoms (hazard ratio [HR] 2.55; 95% confidence interval [CI], 1.90-3.42), sleep disorders (HR 1.95; 95% CI, 1.41-2.70) and other AEs (HR 2.03; 95% CI, 1.51-2.73). Menopausal disorder was not associated with non-persistence (HR 1.17; 95% CI, 0.74-1.84). CONCLUSIONS These results suggest that side-effects of AIs such as musculoskeletal syndrome and sleep disorder lead to ET discontinuation within the first treatment year in significant numbers of EBC patients. Compliance programmes adapted for subgroups that are at risk for early non-persistence might help to ensure the recommended therapy duration. CLINICAL TRIALS NUMBER CFEM345DDE19.
Collapse
Affiliation(s)
- N Nabieva
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - T Fehm
- Department of Gynecology, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany; Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - L Häberle
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Biostatistics Unit, Department of Gynecology, Erlangen University Hospital, Erlangen, Germany
| | - J de Waal
- Department of Gynecology, Dachau Clinic, Dachau, Germany
| | - M Rezai
- Luisen-Hospital Düsseldorf, Düsseldorf, Germany
| | - B Baier
- Department of Gynecology, Dachau Clinic, Dachau, Germany
| | - G Baake
- Oncological Medical Practice Pinneberg, Pinneberg, Germany
| | | | | | - M Warm
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany; Breast Center, Clinics of Cologne GmbH, Holweide, Cologne, Germany
| | - N Harbeck
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany; University Hospital Munich (LMU), Dept. of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich, Germany
| | - R Wuerstlein
- Breast Center, Department of Gynecology, Cologne University Hospital, Cologne, Germany; University Hospital Munich (LMU), Dept. of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich, Germany
| | - J-U Deuker
- Vinzenz-Hospital Hannover GmbH, Hannover, Germany
| | - P Dall
- Department of Gynecology, Lüneburg Clinic, Lüneburg, Germany
| | - B Richter
- Elbland Clinics, Meissen-Radebeul, Germany
| | - G Wachsmann
- County Hospital of Böblingen, Böblingen, Germany
| | - C Brucker
- Department of Gynecology, University Hospital, Paracelsus Private Medical University of Nuremberg, Nuremberg, Germany
| | - J W Siebers
- Department of Gynecology, St. Josef's Hospital, Offenburg, Germany
| | - M Popovic
- Department of Gynecology, Bayreuth Clinic GmbH, CCC ER-EMN, Bayreuth, Germany
| | - T Kuhn
- Karl-Olga-Hospital Stuttgart, Diakonie Klinikum Stuttgart, Stuttgart, Germany
| | - C Wolf
- Medical Center Ulm, Ulm, Germany
| | - H-W Vollert
- Friedrichshafen Clinic, Friedrichshafen, Germany
| | - G-P Breitbach
- Department of Gynecology, Neunkirchen Clinic, Neunkirchen, Germany
| | - W Janni
- Department of Gynecology, Ulm University Hospital, Ulm, Germany
| | - R Landthaler
- Gynecological Medical Practice of the County Hospital of Krumbach, Krumbach, Germany
| | - A Kohls
- Evangelic County Hospital Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany
| | - D Rezek
- Marien-Hospital Wesel, Wesel, Germany
| | - T Noesselt
- Department of Gynecology of the County Hospital of Hameln, Hameln, Germany
| | - G Fischer
- Mittweida Hospital gGmbH, Mittweida, Germany
| | - S Henschen
- Johanniter Hospital Genthin Stendal gGmbH, Hansestadt Stendal, Germany
| | - T Praetz
- Caritas-Hospital Bad Mergentheim, Bad Mergentheim, Germany
| | - V Heyl
- Asklepios Paulinen Clinic Wiesbaden, Wiesbaden, Germany
| | - T Kühn
- Department of Gynecology, Esslingen Clinics a.N., Esslingen, Germany
| | - T Krauss
- Department of Gynecology Passau, Passau, Germany
| | - C Thomssen
- Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany
| | - A Hohn
- County Hospital Kiel GmbH, Kiel, Germany
| | - H Tesch
- Oncology Bethanien Frankfurt, Frankfurt, Germany
| | - C Mundhenke
- Department of Gynecology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - A Hein
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C C Hack
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - K Schmidt
- Novartis Pharma GmbH Nuremberg, Nuremberg, Germany
| | | | - S Y Brucker
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - S Kümmel
- Breast Unit, Essen Mitte Clinics, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany
| | - M W Beckmann
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - D Wallwiener
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - P Hadji
- Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany
| | - P A Fasching
- Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
| |
Collapse
|
30
|
Harbeck N, Villanueva Vázquez R, Tripathy D, Lu Y, De Laurentiis M, Kümmel S, Taylor D, Bardia A, Hurvitz S, Chow L, Im S, Franke F, Hughes G, Miller M, Kong O, Chandiwana D, Colleoni M. Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30260-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
von Waldenfels G, Loibl S, Furlanetto J, Anna M, Lederer B, Denkert C, Hanusch C, Huober J, Jackisch C, Kümmel S, von Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Abstract P6-15-03: Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-15-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Recent studies showed the high and independent impact of age (<40 years) on pathologic complete remission (pCR) and prognosis for patients undergoing neoadjuvant chemotherapy (NACT). Some physicians might not consider elderly patients (>65 years) for NACT due to poor prognosis or higher toxicity. The aim of this analysis is to help selecting appropriately elderly women who would benefit from NACT. Secondly, survival parameters will be investigated in several clinical and histological subgroups.
Methods: From 1998 to 2010, eight prospectively randomized German Breast Group (GBG) trials of anthracycline- and taxane-based NACT were performed and analyzed in this study.
Results: Compared to the overall average, women older than 65 years had significant larger tumors and more overall lymph node involvement. Also, compared to patients younger than 51 years, they had more lobular invasive tumors. Histologically, they had more G2 tumors, more estrogen-receptor positive tumors. PCR (ypT0 ypN0) was strongly associated with age: >65y: 11.7%; 51-65y: 14.1%; 40-50y: 17.3%; <40y: 20.9%. The multivariable logistic regression analysis of clinical parameters showed that young age, clinical stage T4, invasive ductal cancer and poor differentiated breast cancer are predictive for high pCR. The multivariate analyses of molecular subgroups also showed that age >65years is a predictor of significant (p<0.05) lower pCR in TNBC and HR positive/HER2- breast cancers. Nonetheless, in this cohort, HER2+ patients showed pCR rates as high - and for HR+/HER2+ even higher - pCR rates compared to younger patients.
Discussion: This study underlines the unfavorable impact of higher age on pCR, but it shows nevertheless a realistic chance for pCR if NACT is applied - especially for HER2+ patients. Furthermore, elderly patients in this analysis with non-TNBC have a good prognosis (comparable to younger patients) regarding OS, even if they do not have pCR.
Citation Format: von Waldenfels G, Loibl S, Furlanetto J, Anna M, Lederer B, Denkert C, Hanusch C, Huober J, Jackisch C, Kümmel S, von Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-15-03.
Collapse
Affiliation(s)
- G von Waldenfels
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - S Loibl
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - J Furlanetto
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - M Anna
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - B Lederer
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - C Denkert
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - C Hanusch
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - J Huober
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - C Jackisch
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - S Kümmel
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - G von Minckwitz
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - A Schneeweiss
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - M Untch
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - K Rhiem
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - PA Fasching
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| | - JU Blohmer
- Charité University Hospital, Berlin, Germany; German Breast Group, Neu-Isenburg, Hessen, Germany; University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Rotkreuzklinikum Munich, Munich, Bayern, Germany; University Hospital Ulm, Ulm, Baden-Wuerttemberg, Germany; Sana Klinikum Offenbach, Offenbach, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Hospital Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; University Hospital Erlangen, Erlangen, Bayern, Germany
| |
Collapse
|
32
|
Loibl S, Untch M, Denkert C, Huober J, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Rhiem K, Burchardi N, Schneeweiss A. Abstract P6-15-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - M Untch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Denkert
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Huober
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - JU Blohmer
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - E-M Grischke
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Furlanetto
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - H Tesch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Hanusch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - M Rezai
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Jackisch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - WD Schmitt
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - G von Minckwitz
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Thomalla
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - S Kümmel
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - B Rautenberg
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - PA Fasching
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - K Rhiem
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - N Burchardi
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - A Schneeweiss
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| |
Collapse
|
33
|
Janni WJ, Harbeck N, Rack B, Gluz O, Schneeweiss A, Kates R, Fehm T, Kreipe H, Kümmel S, Würstlein R, Hartkopf A, Clemens M, Reimer T, Friedl T, Häberle L, Fasching P, Nitz U. Abstract P6-13-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- WJ Janni
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - N Harbeck
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - B Rack
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - O Gluz
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - A Schneeweiss
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - R Kates
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Fehm
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - H Kreipe
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - S Kümmel
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - R Würstlein
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - A Hartkopf
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - M Clemens
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Reimer
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Friedl
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - L Häberle
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - P Fasching
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - U Nitz
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| |
Collapse
|
34
|
Furlanetto J, Thode C, Huober J, Denkert C, Bassy M, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Untch M, Fasching PA, Karn T, Marmé F, van Mackelenbergh M, Müller V, Schem C, von Minckwitz G, Strik D, Nekljudova V, Loibl S. Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd7-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
We previously demonstrated that the majority of women ≤45 years experienced chemotherapy-induced ovarian failure (CIOF) after CT for EBC. Age, CT regimen, duration and dose-density influenced the rate of CIOF. The regain of premenopausal Follicle-Stimulating Hormone (FSH) and Estradiol (E2) levels after chemotherapy is not equivalent to fertility restoration. The Anti-Muellerian Hormone (AMH) assessment seems to be more accurate than other hormones in predicting the ovarian reserve. FSH, E2 and AMH have been prospectively assessed in young patients receiving (neo)adjuvant CT.
Methods:
740 patients (pts) aged ≤45yrs treated with anthracycline or taxane-based CT for EBC from 4 German neoadjuvant/adjuvant trials were included. Blood samples were collected at baseline before CT (N=740), end of treatment (EOT n=740), 6 (n=177), 12 (n=113), 18 (n=69), 24 (n=47) months (m) after EOT. Only the full set of samples of a given patient was included. FSH, E2 and AMH were centrally assessed. Postmenopausal hormone levels of FSH and E2 according to the central laboratory were defined as FSH>12.4IU/l and E2<52.2ng/l; fertile level of AMH as ≥0.22ng/ml. Regain of premenopausal hormone levels was defined as the time point from EOT to premenopausal FSH and E2 level regain and was assessed only for those pts with postmenopausal FSH and E2 levels at EOT. Pts with no regain have been censored at the date of the last hormone assessment.
Results:
Median age was 40yrs (range 21-45); 57.2% had BMI 18.5-<25, 41.1% ≥25; 32% had luminal-like, 35.9% HER2+, 32.0% triple-negative BC. Median hormone levels at different time points are presented in Table 1. Before chemotherapy 14.2% of pts had non-fertile hormone levels of AMH despite premenopausal levels of FSH and E2 compared to 77.3% of pts with postmenopausal levels (p<0.001); at EOT 77.4% vs 99.8% (p<0.001); at 6m 82.1% vs 100% (p<0.001); at 12m 80.7% vs 98.4% (p=0.002); at 18m 66.7% vs 100% (p<0.001); at 24 m 72.4% vs 100% (p=0.017). Similar results were observed in 47 pts with all time point samples available. Of 147 pts with postmenopausal hormone levels of FSH and E2 at EOT, 32.7% (95%CI 25.7%-40.9%) regained premenopausal hormone levels within 6m, 51.0% (95%CI 42.3%-60.4%) within 12m, 66.6% (95%CI 55.2%-77.6%) within 18m and 69.9% (95%CI 57.8%-81.3%) within 24m.
Conclusion:
Nearly 70% of women regain premenopausal hormone levels of FSH and E2 within 2 years after end of CT. Despite that, only less than one third maintain their fertility potential as predicted by AMH. AMH is a very sensitive marker for the prediction of fertility function after CT for EBC.
Table 1 Median and range of FSH, E2 and AMH levels per time pointsTimepointFSH,IU/lE2, ng/mLAMH, ng/ml% of pts with AMH levels above dtBaseline6.0 [dt-142.7]88.0 [dt-2375.0]0.96 [dt-16.18]95.4EOT76.1 [1.9-225.0]dt [dt-632.0]dt [dt -3.11]15.66 m41.4 [1.1-190.6]10.0 [dt-929.0]dt [dt -3.11]26.112 m28.7 [1.1-146.0]11.0 [dt-947.0]dt [dt -2.81]29.218 m20.6 [0.8-172.3]19.0 [dt-624.0]dt [dt -1.89]34.824 m16.30 [dt-93.9]44.0 [dt-11795.0]dt [dt -1.75]38.3Abbreviations: dt, detectable threshold, EOT, end of treatment; m, month; pts, patients. Detectable threshold: FSH<0.1IU/l, E2<5ng/l, AMH<0.03ng/ml
Citation Format: Furlanetto J, Thode C, Huober J, Denkert C, Bassy M, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Untch M, Fasching PA, Karn T, Marmé F, van Mackelenbergh M, Müller V, Schem C, von Minckwitz G, Strik D, Nekljudova V, Loibl S. Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD7-09.
Collapse
Affiliation(s)
- J Furlanetto
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - C Thode
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - J Huober
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - C Denkert
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - M Bassy
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - C Hanusch
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - C Jackisch
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - S Kümmel
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - A Schneeweiss
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - M Untch
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - PA Fasching
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - T Karn
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - F Marmé
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - M van Mackelenbergh
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - V Müller
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - C Schem
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - G von Minckwitz
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - D Strik
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - V Nekljudova
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| | - S Loibl
- German Breast Group Neu-Isenburg; Amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Medizinische Mikrobiologie und Immunologie Göttingen; Universitätsklinikum Ulm; Charite Berlin; Klinikum zum Roten Kreuz München; SANA Klinikum Offenbach; Kliniken Essen-Mitte; Universitätsklinikum Heidelberg; Helios Kliniken Berlin-Buch; University Hospital Erlangen; Universitätsklinikum Frankfurt; Universitätsklinikums Schleswig-Holstein Kiel; Universitätsklinikum Hamburg; Endokrinologikum Berlin
| |
Collapse
|
35
|
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R, Emons G, Kriner M, Elling D, Blohmer JU, Thomas A. Significant Changes in Circulating Plasma Levels of IGF1 and IGFBP3 after Conventional or Dose-Intensified Adjuvant Treatment of Breast Cancer Patients with one to three Positive Lymph Nodes. Int J Biol Markers 2018; 22:186-93. [DOI: 10.1177/172460080702200304] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The insulin-like growth factor 1 (IGF1) and its binding protein IGFBP3 (insulin-like growth factor binding protein 3) play a pivotal role during the growth and development of tissues. The purpose of this study was to evaluate the influence of anthracycline- and taxane-containing adjuvant chemotherapy in breast cancer patients on the circulating plasma levels of IGF1 and its main binding protein, IGFBP3. This investigation was part of a prospective randomized phase III study in which breast cancer patients were treated with either conventional or dose-intensified adjuvant chemotherapy. The factors were quantified in the plasma of 151 patients with a commercially available sandwich enzyme immunoassay. Before therapy, both parameters were within the normal range in most patients (n=145 and n=144). After therapy, both factors had increased significantly by 29% (IGF1) and 19% (IGFBP3), with the highest increase being observed in the dose-intensified group. Correlations with patient and tumor characteristics revealed a relatively higher increase in both parameters in premenopausal patients, patients with lower-grade tumors, more positive lymph nodes, larger tumor volume, and positive hormone receptor status. No correlation was found with the HER2 expression of the tumors.
Collapse
Affiliation(s)
- S. Kümmel
- Department of Obstetrics and Gynecology, University of Duisburg-Essen, Essen
| | - H. Eggemann
- Department of Obstetrics and Gynecology Otto von Guericke University Magdeburg, Magdeburg
| | - D. Lüftner
- Department of Hematology and Oncology, University Medicine Berlin, Campus Charité Mitte, Berlin
| | - N. Gebauer
- Department of Obstetrics and Gynecology, University of Duisburg-Essen, Essen
| | - H. Bühler
- Ruhr University Bochum, Bochum - Germany
| | | | - P. Schmid
- Charing Cross and Hammersmith Hospital, Imperial College, London - United Kingdom
| | - R. Kreienberg
- Department of Obstetrics and Gynecology, University Ulm, Ulm
| | - G. Emons
- Department of Obstetrics and Gynecology, Georg-august University Göttingen, Göttingen
| | - M. Kriner
- Department of Medical Statistics and Epidemiology, Technical University Munich, Munich
| | - D. Elling
- Department of Obstetrics and Gynecology, Berlin-Lichtenberg Hospital, Berlin
| | - J.-U. Blohmer
- Department of Obstetrics and Gynecology, University of Duisburg-Essen, Essen
| | - A. Thomas
- Department of Obstetrics and Gynecology, University of Duisburg-Essen, Essen
| |
Collapse
|
36
|
Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Dan Costa S, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol 2017; 28:497-504. [PMID: 27831502 DOI: 10.1093/annonc/mdw610] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n = 396) in comparison to the HER2- cohort. Patients and methods Patients with histologically confirmed breast cancer (n = 1206) received four cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+ tumors. The primary endpoint was pCR defined as ypT0 ypN0. Results Higher rates of pCR were achieved in HER2+ than in HER2- tumors (57.8% versus 22.0%, P < 0.0001), with the highest rate in the HER2+/HR- cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). Grade ≥3 toxic effects were significantly more common in HER2+ than in HER2- patients, with grade 3-4 diarrhea in 7.6% versus 0.9% (P < 0.001) and febrile neutropenia in 6.3% versus 3.3% (P = 0.023) of patients. Left ventricular ejection fraction decreases from baseline were uncommon, with 2.0% versus 0.4% of patients showing decreases to <50% along with a ≥10% decrease from baseline. Conclusion In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, , Germany
| | - C Jackisch
- Department of Obstetrics & Gynecology, Sana Klinikum, Offenbach, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital, Heidelberg, , Germany
| | - S Schmatloch
- Breast Cancer Center, Elisabeth Krankenhausx, Weinbergstraße 7, Kassel, Germany
| | - B Aktas
- Department of Gynecology & Obstetrics, University Women's Hospital Essen, Essen, Germany
| | - C Denkert
- Department of Pathology, University Hospital Charité, Berlin, Germany
| | - H Wiebringhaus
- Gynecology, St. Barbara-Klinik Hamm-Heessen, Hamm, Germany
| | - S Kümmel
- Breast Unit, Interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany
| | - M Warm
- Breast Unit, Brustzentrum im Krankenhaus Köln-Holweide, Köln, Germany
| | - S Paepke
- Women's Clinic, Klinikum Rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Germany
| | - M Just
- Oncology, Onkologische Schwerpunktpraxis Bielefeld, Germany
| | - C Hanusch
- Women's Clinic, Klinikum zum Roten Kreuz, München, Germany
| | - J Hackmann
- Breast Unit, Marien Hospital Witten, Witten, Germany
| | - J-U Blohmer
- Women's Clinic, Klinik für Gynäkologie am Campus Charité Mitte, Berlin, Germany
| | - M Clemens
- Women's Clinic, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany
| | - S Dan Costa
- Department of Gynecology, Universitäts-Frauenklinik, Magdeburg, Germany
| | - B Gerber
- Women's Clinic, Universitäts-Frauenklinik, Rostock, Germany
| | - K Engels
- Department of Pathology, Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Germany
| | | | | | - M Untch
- Department of Gynecology and Obstetrics, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | | |
Collapse
|
37
|
Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187. [PMID: 29177689 DOI: 10.1007/s10549-017-4581-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 11/15/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin D1 overexpression in residual tumor could recognize those patients that benefit most from such post-neoadjuvant treatment. In this study, we determined Cyclin D1 expression in residual BC after NACT. Secondary aims were to correlate Cyclin D1 expression levels with clinicopathological parameters and to assess its prognostic value after NACT. METHODS We retrospectively assessed the nuclear expression of Cyclin D1 on tissue microarrays with residual tumor from 284 patients treated in the neoadjuvant GeparTrio (n = 186) and GeparQuattro (n = 98) trials. Evaluation was performed with a standardized immunoreactive score (IRS) after selecting a cut-off value. RESULTS A high expression level (IRS ≥ 6) of Cyclin D1 was found in 37.3% of the assessed specimens. An increased Cyclin D1 expression was observed in HR-positive tumors, compared to HR-negative tumors (p = 0.02). Low Cyclin D1 levels correlated with clinical tumor stage 1-3 (p = 0.03). Among patients with HR-positive/Her2-negative tumors and high Cyclin D1 expression, a better disease-free survival (DFS) was graphically suggested, but not significant (p = 0.21). CONCLUSION Our study demonstrates a measurable nuclear expression of Cyclin D1 in post-neoadjuvant residual tumor tissue of HR-positive BC. Cyclin D1 expression was not prognostic for DFS after NACT. Our results and defined cut-off suggest that the marker can be used to stratify tumors according to protein expression levels. Based on this, a prospective evaluation is currently performed in the ongoing Penelope-B trial.
Collapse
Affiliation(s)
- S L Villegas
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - S Darb-Esfahani
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.,Institute of Pathology Spandau, Evangelisches Waldkrankenhaus, Stadtrandstr. 555, 13589, Berlin, Germany
| | - G von Minckwitz
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - J Huober
- Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany
| | - K Weber
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - F Marmé
- National Center for Tumor Diseases, University-Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
| | - J Furlanetto
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - C Schem
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Hostein, Kiel, Germany
| | - B M Pfitzner
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - B Lederer
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - K Engels
- Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss, Germany
| | - S Kümmel
- Breast Unit Kliniken Essen-Mitte, Essen, Germany
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany
| | - K Mehta
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| | - C Denkert
- Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. .,German Cancer Consortium (DKTK), Partner Site Charité, Berlin, Germany.
| | - S Loibl
- German Breast Group (GBG Forschungs GmbH), Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany
| |
Collapse
|
38
|
Lux MP, Nabieva N, Hildebrandt T, Rebscher H, Kümmel S, Blohmer JU, Schrauder MG. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany. Breast 2017; 37:89-98. [PMID: 29128582 DOI: 10.1016/j.breast.2017.11.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Revised: 10/31/2017] [Accepted: 11/01/2017] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVES Many women with early-stage, hormone receptor-positive breast cancer may not benefit from adjuvant chemotherapy. Gene expression tests can reduce chemotherapy over- and undertreatment by providing prognostic information on the likelihood of recurrence and, with Oncotype DX, predictive information on chemotherapy benefit. These tests are currently not reimbursed by German healthcare payers. An analysis was conducted to evaluate the budget impact of gene expression tests in Germany. MATERIALS AND METHODS Costs of gene expression tests and medical and non-medical costs associated with treatment were assessed from healthcare payer and societal perspectives. Costs were estimated from data collected at a university hospital and were combined with decision impact data for Oncotype DX, MammaPrint, Prosigna and EndoPredict (EPclin). Changes in chemotherapy use and budget impact were evaluated over 1 year for 20,000 women. RESULTS Chemotherapy was associated with substantial annual costs of EUR 19,003 and EUR 84,412 per therapy from the healthcare payer and societal perspective, respectively. Compared with standard care, only Oncotype DX was associated with cost savings to healthcare payers and society (EUR 5.9 million and EUR 253 million, respectively). Scenario analysis showed that both women at high clinical but low genomic risk and low clinical but high genomic risk were important contributors to costs. CONCLUSIONS Oncotype DX was the only gene expression test that was estimated to reduce costs versus standard care in Germany. The reimbursement of Oncotype DX testing in standard clinical practice in Germany should be considered.
Collapse
Affiliation(s)
- M P Lux
- Universitäts-Brustzentrum Franken, Frauenklinik, Universitätsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
| | - N Nabieva
- Universitäts-Brustzentrum Franken, Frauenklinik, Universitätsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - T Hildebrandt
- Universitäts-Brustzentrum Franken, Frauenklinik, Universitätsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - H Rebscher
- Institut für Gesundheitsökonomie und Versorgungsforschung, Gyhum-Hesedorf, Germany
| | - S Kümmel
- Interdisziplinäres Brust-/Krebszentrum, Kliniken Essen-Mitte, Essen, Germany
| | - J-U Blohmer
- Klinik für Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - M G Schrauder
- Universitäts-Brustzentrum Franken, Frauenklinik, Universitätsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| |
Collapse
|
39
|
Gluz O, Nitz U, Christgen M, Malter W, Clemens M, Reimer T, Nuding B, Aktas B, Stefek A, Ppllmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kümmel S, Liedtke C, Shak S, Kates R, Wurstlein R, Kreipe H, Harbeck N. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux M. Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Lüdtke-Heckenkamp K, Kümmel S, Ruf-Dördelmann A, Distelrath A, Wacker J, Schmatloch S, Busch-Liles S, Schmidt M. Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Lux M, Schrauder M, Hildebrandt T, Nabieva N, Kümmel S, Blohmer JU. Comparative budget impact assessment of the different breast cancer genomic tests in Germany. Breast 2017. [DOI: 10.1016/s0960-9776(17)30327-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
43
|
Harbeck N, Nitz UA, Matthias C, Kates R, Braun M, Kümmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, Liedtke C, Grischke EM, de Haas SL, Deurloo R, Schumacher J, Wuerstlein R, Kreipe HH, Gluz O. Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immune and apoptosis biomarkers are potential prognostic/predictive markers in HER2+ EBC. High PD-L1 expression was shown to be predictive for lower pCR after chemotherapy+trastuzumab+/-pertuzumab, particularly in HER2+, ER- disease. Yet, HER2+ EBC co-expressing hormone receptors is a distinct entity.
The ADAPT HER2+/HR+ phase II trial (n=376) compared 12 weeks of neoadjuvant T-DM1 + ET vs. trastuzumab (T)+ET and demonstrated pCR rates of about 41% in both (well tolerated) T-DM1 arms.
Methods: In order to identify potential early predictors for pCR (i.e. no invasive tumor in breast and lymph nodes), immune markers (PDL1 on infiltrating immune cells (IIC) and on tumor cells (TC); CD8 in invasive margin and in tumor center) and apoptosis markers (bcl-2; mcl-2) were determined by immunohistochemistry (IHC; H-scores) in core biopsy sections obtained at primary diagnosis and at cycle 2. For multivariate logistic regression, each biomarker (separately), clinical factors (Ki-67, cT, cN) and therapy were entered. All analyses were exploratory.
Results:Biomarkers were available in up to 326 patients (pts) at baseline and up to 170 pts at 3 weeks (due to low tumor content in 2nd core biopsy).
Baseline IIC-PDL1 was associated with pCR in the T-DM1 arm (OR 2.89; 95%CI: 1.11-7.51); IIC-PDL1 at cycle 2 was not associated with pCR.
PD-L1 expression in TC was rare (2%); cycle-2 TC-PD-L1 was associated with pCR in all pts and in the pooled TDM-1 arms.
High baseline CD8 in tumor center was associated with pCR in the whole cohort (OR 2.4; CI: 1.04 – 5.5) and in the T+ET arm (OR=10.1; CI: 1.12 - 91.6) and at cycle 2 in all pts (OR=9.52; CI: 2.17 – 41), in pooled TDM-1 arms (OR=15.7; CI: 2.49 – 99), and in TDM-1+ET (OR=25.05; CI: 2.12 – 295). Increases in this marker also predicted pCR in all pts, pooled TDM-1, and in TDM-1+ET. Association of cycle-2 CD8 in tumor center with pCR persisted in multivariate models.
Lower baseline CD8 in invasive margin was associated with pCR in the T-DM1 arm (OR=0.09; CI: 0.01-0.69), but at cycle 2 in all pts (OR=18.1; CI: 1.60 – 204) and in pooled TDM-1 arms (OR=23.5; CI: 1.1 - 500). This positive impact persisted in multivariate models.
Bcl-2 expression at baseline was associated with non-pCR in all pts (OR=0.28, CI: 0.12 - 0.66), in the pooled T-DM1 arms (OR=0.216, CI: 0.08 - 0.61), and particularly in the T-DM1+ET arm (OR=0.14; CI: 0.03 - 0.71). This association persisted in multivariate analysis. At cycle 2, lower bcl-2 had OR=0.16 (CI: 0.03 - 0.96) in the pooled T-DM1 arms. No association with efficacy was seen for mcl-1.
Conclusions: The WSG-ADAPT HER2+/HR+ phase II trial is the first international trial to focus on HER2+/HR+ EBC alone and the first to show substantial pCR rates of > 40% after only 12 weeks of T-DM1 -- without standard chemotherapy.
Expression of bcl-2 may affect resistance to T-DM1. High immune activity at baseline and/or cycle 2 seems to be associated with pCR. The association of CD8 expression and its changes with therapy efficacy is complex and could depend on ET.
Further biomarker analyses are ongoing and will be presented at the meeting.
Citation Format: Harbeck N, Nitz UA, Matthias C, Kates R, Braun M, Kümmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, Liedtke C, Grischke E-M, de Haas SL, Deurloo R, Schumacher J, Wuerstlein R, Kreipe HH, Gluz O. The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-05.
Collapse
Affiliation(s)
- N Harbeck
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - UA Nitz
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - C Matthias
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - R Kates
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - M Braun
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - S Kümmel
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - C Schumacher
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - J Potenberg
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - S Kraemer
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - A Kleine-Tebbe
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - D Augustin
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - B Aktas
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - H Forstbauer
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - J Tio
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - C Liedtke
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - E-M Grischke
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - SL de Haas
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - R Deurloo
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - J Schumacher
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - R Wuerstlein
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - HH Kreipe
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| | - O Gluz
- Breast Center, University of Munich and CCCLMU, Munich, Bavaria, Germany; West German Study Group, Moenchengladbach, North Rhine Westfalia, Germany; Medical School Hannover, Institute of Pathology, Hannover, Niedersachsen, Germany; Rotkreuz Clinic Munich, Breast Center, Munich, Bavaria, Germany; Clinics Essen-Mitte Breast Center, Essen, North Rhine Westfalia, Germany; St. Elisabeth Hospital Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinic Cologne, Breast Center, Cologne, North Rhine Westfalia, Germany; DRK Clinic Berlin Koepenick, Breast Center, Berlin, Germany; Clinic Deggendorf, Breast Center, Deggendorf, Bavaria, Germany; University Clinic Essen, Women's Clinic, Essen, North Rhine Westfalia, Germany; Oncology Practice Network Troisdorf, Troisdorf, North Rhine Westfalia, Germany; University Clinic Muenster, Women's Clinic, Muenster, North Rhine Westfalia, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Cli
| |
Collapse
|
44
|
van Mackelenberg M, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S. Abstract P1-09-11: Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients – A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The estrogen receptor (ER) as a nuclear transcription factor alters the transcription of estrogen sensitive genes to which the progesterone receptor gene belongs. The ER has also been described to exert non genomic effects by interacting with several cell signalling pathways that do not initially involve increases in gene transcription. These different patterns of action of the ER lead to the assumption that in tumors that utilize the non-genomic ER activity in order to stimulate tumorigenesis and proliferation progesterone receptor (PgR) expression would be decreased or absent. Therefore lack of PgR expression could be a surrogate marker of altered growth factor signalling. The aim of this study was to investigate if PgR expression may act as a predictive factor for response to neoadjuvant chemotherapy and long-term outcome in breast cancer patients.
Methods
5613 patients with primary breast cancer, follow-up, positive ER expression; HER2+ and HER2- from overall 10 (n=9785) German neoadjuvant trials receiving an anthracycline and taxane based chemotherapy were included. The pathologic complete response (pCR)(ypT0, ypN0), long term survival data (disease free survival (DFS), distant disease free survival (DDFS), overall survival (OS) and local recurrence free survival (LRFS)) and early relapse, defined as DFS <37 months, were compared according to their PgR expression, overall and in subgroups defined by HER2.
Results
Tumors lacking PgR expression (1172 patients) were more often of grade 3 (38.4% v 26.3%; p<0.001), tended to have an advanced clinical nodal involvement (6.8% v 4.7%; p=0.004) and were more likely to demonstrate HER2 positivity (36.2% v 22.3%; p<0.001).
pCR rates were significantly higher in PgR negative patients in the entire cohort (13.8% v 7.5%; p<0.001) as well as in the HER2 negative subgroup (11.2% v 5.8%; p<0.001) whereas there was no significant difference in the HER2 positive (22.1% v 18%; p=0.117). After adjusting for known predictive factors in the multivariable logistic regression analysis PgR negativity was an independent predictive factor for pCR overall (OR 1.76; p<0.001) and in the HER2 negative patients (OR 1.99; p<0.001).
PgR negativity was also significantly associated with an early relapse overall (32.8% v 25.7%; p<0.001) and in the subgroups defined by HER2 (HER2- 32.2% v 24.9%; p<0.001 and HER2+ 39.9%v 30.5%; p=0.002).
Patients with PgR negative disease had a significantly worse DFS, OS, DDFS and LRFS (p<0.001, respectively). Multivariable Cox regression analysis revealed that PgR was an independent prognostic factor. This was also observed in the HER2+ and- subgroups. Interestingly, in the PgR negative tumors HER2 status did not influence long-term outcome.
Conclusion
This analysis demonstrates that ER positive and PgR negative tumors represent a specific subset in primary breast cancer patients associated with higher response but also worse long term outcome after neoadjuvant chemotherapy. Interestingly, PgR negativity served as an independent predictive factor for achieving a pCR after neoadjuvant chemotherapy and therefore its status should be considered when deciding on systemic treatment.
Citation Format: van Mackelenberg M, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P, Blohmer J-U, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S. Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients – A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-11.
Collapse
Affiliation(s)
- M van Mackelenberg
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - C Denkert
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - V Nekljudova
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - T Karn
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - C Schem
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - F Marme
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - E Stickeler
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - C Jackisch
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - C Hanusch
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - J Huober
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - P Fasching
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - S Kümmel
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - V Müller
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - M Untch
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - G von Minckwitz
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - K Weber
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| | - S Loibl
- German Breast Group, Neu-Isenburg; Charite Berlin; Universitätsklinikum Frankfurt; Universitätsklinikum Schleswig-Holstein Kiel; Universitätsklinikum Heidelberg; Universitätsklinikum Aachen; Sana Klinikum Offenbach; Universitätsklinikum München; Universitätsklinikum Ulm; Universitätsklinikum Erlangen; Kliniken Essen-Mitte, Essen; Universitätsklinikum Hamburg; Helios Kliniken Berlin-Buch
| |
Collapse
|
45
|
Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Ingold-Heppner B, Thomalla J, Blohmer JU, Rezai M, Nekljudova V, von Minckwitz G, Loibl S. Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- A Schneeweiss
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - V Möbus
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - H Tesch
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - C Hanusch
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - C Denkert
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - K Lübbe
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - J Huober
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - P Klare
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - S Kümmel
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - M Untch
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - K Kast
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - C Jackisch
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - B Ingold-Heppner
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - J Thomalla
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - J-U Blohmer
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - M Rezai
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - V Nekljudova
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - G von Minckwitz
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| | - S Loibl
- Universitätsklinikum Heidelberg; Klinikum Frankfurt-Höchst; Hämatologisch-Onkologische Gemeinschaftspraxis, Frankfurt; Klinikum zum Roten Kreuz, München; Charite Berlin; Diakovere Henriettenstift Hannover; Universitätsklinikum Ulm; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin; Kliniken Essen- Mitte, Essen; Helios Kliniken Berlin-Buch; Universitätsklinikum Dresden; Sana Klinikum Offenbach; Praxisklinik für Hämatologie und Onkologie Koblenz; Luisenkrankenhaus Düsseldorf; German Breast Group, Neu-Isenburg
| |
Collapse
|
46
|
von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman AR, Nekljudova V, Weber KE, Loibl S. Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Addition of carboplatin to anthracycline/taxane-based neoadjuvant chemotherapy has shown to improve pathological complete response (pCR; ypT0 ypN0) rates in patients with triple-negative breast cancer (TNBC) in two large phase II studies (GeparSixto: von Minckwitz et al, Lancet Oncol 2014, CALGB 40603: Sikov WM, J Clin Oncol 2015). Participants of the GeparSixto study showed an improvement of pCR rate from 36.9 to 53.2% (p=0.005) and DFS by absolute 9% (HR 0.56 95% CI 0.33-0.96] p=0.035) with the addition of carboplatin in the TNBC subgroup. No effect was observed in the HER2-positive subgroup. We here report results on homologous repair deficiency (HRD) status in relation to pCR and DFS in the TNBC subgroup.
Patients and Methods
In the GeparSixto trial (NCT01426880), patients were treated for 18 weeks with paclitaxel 80mg/m2 q1w and non-pegylated-liposomal doxorubicin (NPLD) 20mg/m2 q1w. Patients with TNBC (N=315) received concurrently bevacizumab 15mg/kg i.v. q2w until surgery. All patients were randomized 1:1 to receive concurrently carboplatin AUC 1.5-2 q1w vs no carboplatin. Carboplatin dose was reduced from AUC 2.0 to 1.5 by an amendment after 330 patients. Primary objective is pCR rate (ypT0 ypN0). Event free survival (EFS), and overall survival (OS) were secondary objectives. HR Deficiency status was assessed on FFPE material from pretherapeutic core biopsies. HR Deficiency was defined as either HRD score high or a BRCA mutation.
Results
HRD status was measurable in 193 of 315 TNBC patients. 101 patients of them were randomly assigned to receive carboplatin and 92 to no additional carboplatin. After median follow-up of 34.3 months 43 event free survival (EFS) events have been reported.
HR deficiency was detected in 136 (70.5%) tumors of which 79 (58.1%) showed high HRD score with intact tBRCA. HR deficiency independently predicted pCR (ypT0is ypN0) (odds ratio (OR) 2.506, CI 1.243-5.051, p=0.009). Adding carboplatin to PM significantly increased the pCR rate from 36.6% to 63.2% in HR deficient tumors with intact tBRCA (p=0.018), only marginally from 61.9% to 72.7% in BRCA mutated tumors (p=0.406), and moderately from 20.0% to 40.7% in HR non-deficient tumors (p=0.086). In general, patients with HRD deficient tumors had a better ESF than non HRD deficient ones (HR 1.805 (0.985-3.309); p=0.0526). Patients with high HRD score had an insignificant trend towards an improved EFS compared to those with low HRD score (HR 1.546 (0.764-3.127) p=0.2223). HRD deficiency did not predict carboplatin effect in patients without BRCA mutation (HR 0.8617). In multivariable analysis, only therapy, clinical nodal status before treatment, and lymphocyte predominant breast cancer were significant prognostic on EFS.
Conclusion
Within the GeparSixto study HR deficiency (either HRD score high or BRCA mutation) was associated with a higher pCR in general and an improved EFS. The effect of carboplatin could not be predicted by HR deficiency in this relatively small study. However, the results will help to understand the role of HR deficiency and the value of the HRD score in TNBC especially in patients without BRCA mutation.
Citation Format: von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-02.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - K Timms
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - EP Elkin
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - E Hahnen
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - PA Fasching
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - CT Salat
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Rezai
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - D-M Zahm
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - B Gerber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - P Klare
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Kümmel
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Paepke
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - R Schmutzler
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Chau
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J Reid
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A-R Hartman
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - V Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - KE Weber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| |
Collapse
|
47
|
Dauth M, Graus M, Schelter I, Wießner M, Schöll A, Reinert F, Kümmel S. Perpendicular Emission, Dichroism, and Energy Dependence in Angle-Resolved Photoemission: The Importance of The Final State. Phys Rev Lett 2016; 117:183001. [PMID: 27834988 DOI: 10.1103/physrevlett.117.183001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Indexed: 06/06/2023]
Abstract
Angle-resolved photoemission spectroscopy has been developed to a very high accuracy. However, effects that depend sensitively on the state of the emitted photoelectron were so far hard to compute for real molecules. We here show that the real-time propagation approach to time-dependent density functional theory allows us to obtain final-state effects consistently from first principles and with an accuracy that allows for the interpretation of experimental data. In a combined theoretical and experimental study we demonstrate that the approach captures three hallmark effects that are beyond the final-state plane-wave approximation: emission perpendicular to the light polarization, circular dichroism in the photoelectron angular distribution, and a pronounced energy dependence of the photoemission intensity.
Collapse
Affiliation(s)
- M Dauth
- Theoretical Physics IV, University of Bayreuth, D-95440 Bayreuth, Germany
| | - M Graus
- Experimental Physics VII, University of Würzburg, D-97074 Würzburg, Germany
| | - I Schelter
- Theoretical Physics IV, University of Bayreuth, D-95440 Bayreuth, Germany
| | - M Wießner
- Experimental Physics VII, University of Würzburg, D-97074 Würzburg, Germany
| | - A Schöll
- Experimental Physics VII, University of Würzburg, D-97074 Würzburg, Germany
| | - F Reinert
- Experimental Physics VII, University of Würzburg, D-97074 Würzburg, Germany
| | - S Kümmel
- Theoretical Physics IV, University of Bayreuth, D-95440 Bayreuth, Germany
| |
Collapse
|
48
|
Grischke EM, Nusch A, Marschner N, Abenhardt W, Wilke J, Decker T, Just M, Kümmel S, Kurbacher C, Marmé F, Overkamp F, Xuan F, Miller M, Janni W. Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Hack CC, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Wallwiener D, Paepke D, Kümmel S, Beckmann MW. Interest in integrative medicine among postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment in the EvAluate-TM study. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
50
|
Rhiem K, Richters L, Hahnen E, Lampe B, Rezai M, Göhring UJ, Schumacher C, Kümmel S, Ataseven B, Schmutzler R. Benchmarking der Checkliste zur Erfassung einer erblichen Belastung für Brust- und/oder Eierstockkrebs. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|